RxDoctor Payments Data

Elizabeth Cilenti, MD

Internal Medicine · Arlington, VANPI 1124287776

Payments from drug & device makers

$1,784in general payments, 2019–2025

Across 79 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$429
  • Amgen$344
  • AbbVie$242
  • Lilly USA, LLC$214
  • Pfizer$172
  • Exact Sciences$117
  • plus $267 from 7 others

What the payments were for

  • Food & beverage$1,784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk19$429
Amgen15$344
AbbVie9$242
Lilly USA, LLC11$214
Pfizer8$172
Exact Sciences4$117
Astellas Pharma US Inc4$89
AstraZeneca3$60
Bayer2$43
Bausch Health US, LLC1$21
GSK1$19
Watermark Medical, Inc.1$19
Sanofi Pasteur Inc.1$16

How this compares

$1,784 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$50,416
Medicare patients
87
Services billed
694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate17$17,150
Rosuvastatin Calcium38$833
Levothyroxine Sodium42$475
Olmesartan Medoxomil14$301
Atorvastatin Calcium24$245
Duloxetine Hcl19$219
Omeprazole21$189
Amlodipine Besylate16$176
Lisinopril15$164
Escitalopram Oxalate12$151
Gabapentin11$113
Trazodone Hcl12$58
Metformin Hcl ErMetformin Hcl11$43
Hydrochlorothiazide15$13

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$172$17,15017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →